Q3 Earnings Estimate for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS) – Equities researchers at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for shares of 908 Devices in a research note issued on Monday, May 19th. William Blair analyst M. Larew now anticipates that the company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.09). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices’ Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.09) EPS.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The business had revenue of $11.78 million during the quarter, compared to analysts’ expectations of $11.90 million.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research note on Saturday, May 10th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Stock Down 5.9%

MASS opened at $4.65 on Wednesday. The firm has a market cap of $166.75 million, a P/E ratio of -2.63 and a beta of 0.26. 908 Devices has a 52 week low of $1.81 and a 52 week high of $6.86. The business’s fifty day simple moving average is $4.63 and its 200 day simple moving average is $3.30.

Hedge Funds Weigh In On 908 Devices

A number of hedge funds have recently bought and sold shares of MASS. Two Sigma Advisers LP acquired a new position in 908 Devices in the fourth quarter worth about $30,000. CWM LLC boosted its stake in 908 Devices by 541.2% in the first quarter. CWM LLC now owns 6,963 shares of the company’s stock valued at $31,000 after acquiring an additional 5,877 shares during the period. Prudential Financial Inc. acquired a new position in 908 Devices in the fourth quarter valued at approximately $34,000. Occudo Quantitative Strategies LP acquired a new position in 908 Devices in the fourth quarter valued at approximately $36,000. Finally, Two Sigma Investments LP acquired a new position in 908 Devices in the fourth quarter valued at approximately $42,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Mark Spoto purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The stock was acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the purchase, the director now owns 62,971 shares of the company’s stock, valued at approximately $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.70% of the stock is currently owned by company insiders.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.